Skip to main content

A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Status: closed to accrual

INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.

Inclusion Criteria

Histologically or cytologically-documented solid tumors.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
Demonstrate adequate organ function.

Exclusion Criteria

Prior history of or active malignant disease other than that being treated in this study.
Known brain metastases or cranial epidural disease.
A known hypersensitivity to the components of the study therapy or its' analogs.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.